Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Gina Consylman sold 3,594 shares of the stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $14.66, for a total transaction of $52,688.04. Following the completion of the sale, the chief financial officer now owns 59,125 shares of the company’s stock, valued at approximately $866,772.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded down $0.15 during midday trading on Friday, hitting $14.68. 791,236 shares of the stock were exchanged, compared to its average volume of 1,823,020. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31. Ironwood Pharmaceuticals, Inc. has a one year low of $12.89 and a one year high of $19.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $94.20 million during the quarter, compared to analysts’ expectations of $88.86 million. Ironwood Pharmaceuticals had a negative net margin of 39.20% and a negative return on equity of 2,458.64%. Ironwood Pharmaceuticals’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.12) EPS. equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post -0.45 earnings per share for the current year.
IRWD has been the subject of a number of recent analyst reports. ValuEngine cut shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Credit Suisse Group initiated coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $19.00 price target for the company. Morgan Stanley reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 4th. Mizuho cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $20.00 to $16.00 in a research note on Wednesday, December 6th. Finally, BidaskClub cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $17.75.
Several hedge funds and other institutional investors have recently bought and sold shares of IRWD. Sarissa Capital Management LP acquired a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $24,733,000. Senzar Asset Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 185.8% during the 4th quarter. Senzar Asset Management LLC now owns 1,448,800 shares of the biotechnology company’s stock worth $21,718,000 after buying an additional 941,800 shares during the last quarter. Pictet Asset Management Ltd. lifted its stake in shares of Ironwood Pharmaceuticals by 37.5% during the 3rd quarter. Pictet Asset Management Ltd. now owns 2,622,507 shares of the biotechnology company’s stock worth $41,357,000 after buying an additional 715,147 shares during the last quarter. Park West Asset Management LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $9,203,000. Finally, State Street Corp lifted its stake in shares of Ironwood Pharmaceuticals by 13.7% during the 2nd quarter. State Street Corp now owns 4,530,267 shares of the biotechnology company’s stock worth $85,533,000 after buying an additional 545,464 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: “Gina Consylman Sells 3,594 Shares of Ironwood Pharmaceuticals, Inc. (IRWD) Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/02/23/gina-consylman-sells-3594-shares-of-ironwood-pharmaceuticals-inc-irwd-stock.html.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.